Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David Fisher, Richard Kaplan, Phil Quirke, Susan Richman, Leslie Samuel, Jenny Seligman, Matt Seymour, Kai Keen Shui, Harpreet Wasan, Richard Wilson, Tim Maughan

Research output: Contribution to journalArticle

17 Citations (Scopus)
6 Downloads (Pure)
Original languageEnglish
Pages (from-to)162–171
Number of pages9
JournalThe Lancet Gastroenterology & Hepatology
Volume3
Issue number3
Early online date15 Dec 2017
DOIs
Publication statusPublished - Mar 2018

Keywords

  • colorectal cancer
  • biomarkers
  • therapeutic efficacy
  • EGFR inhibitors

Cite this

Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., Kaplan, R., Quirke, P., Richman, S., Samuel, L., Seligman, J., Seymour, M., Shui, K. K., Wasan, H., Wilson, R., & Maughan, T. (2018). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet Gastroenterology & Hepatology, 3(3), 162–171. https://doi.org/10.1016/S2468-1253(17)30394-1